---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-006481"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:28:33.800278+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCardia reports positive echo results from Phase III HFrEF trial; reduced ventricular remodeling

## Summary
- CardiAMP cell therapy reduced left ventricular end-diastolic volume (p=0.06) and end-systolic volume (p=0.09).
- In patients with elevated NTproBNP, volume reductions were clinically meaningful and statistically significant (p=0.02, p=0.01).
- Results correlated with reduced major adverse cardiovascular events and improved quality of life.
- Echocardiography outcomes by Yale core lab; data presented at THT 2026.

## SEC filing metadata
- accession: 0001437749-26-006481
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774926006481/0001437749-26-006481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774926006481/bcda20260303_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-006481
- JSON: https://secwatch.observer/filing/0001437749-26-006481.json
- Plain text: https://secwatch.observer/filing/0001437749-26-006481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.